Compare ARK Next Generation Internet ETF (ARKW) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Next Generation Internet ETF vs Sanofi SA — how do they compare? ARK Next Generation Internet ETF trades at $151.09, while Sanofi SA trades at $43.61 (market cap $104.30B). The key difference: Sanofi SA pays a 5.55% dividend while ARK Next Generation Internet ETF pays none, and ARK Next Generation Internet ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| ARKW | SNY | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $182.20 | $52.34 |
52-Week Low | $114.45 | $41.33 |
Market Cap | — | $104.30B |
Enterprise Value | — | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKW trades at $151.00, up 0.95% with bullish technical signals from moving averages. The ETF faces near-term headwinds from elevated AI infrastructure spending but maintains long-term growth potential through holdings like AMD and TSLA. Technical indicators show mixed signals with RSI suggesting potential overbought conditions while ADX indicates strong trend strength.
The ETF's outlook balances near-term capital expenditure pressures against long-term AI growth opportunities. Key risks include market skepticism toward tech valuations and sector volatility, while institutional interest in AI exposure provides support. Current positioning near resistance at $152 suggests potential for consolidation before next directional move.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Next Generation Internet ETF
ARKW is an actively managed ETF that invests in next-generation internet technologies. It focuses on cloud computing, AI, e-commerce, and blockchain innovation, with key holdings like Tesla, Advanced Micro Devices, and Roku.
Read more on ARKW →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
